Search Results

IDE Approved for Pivotal Trial of BiO2 Medical's Angel Catheter

January 8, 2015—BiO2 Medical announced approval of an investigational device exemption (IDE) from the US food and Drug Administration to initiate a clinical investigation of the company’s Angel catheter for pulmonary embolism (PE) protection in high-risk patients.

FLARE Study of Inari Medical's FlowTriever for Pulmonary Embolism Completes Enrollment

October 24, 2017—Inari Medical, Inc. recently announced that it has completed enrollment of the FLARE study, which is designed to evaluate the safety and effectiveness of the company's FlowTriever retrieval/aspiration system for the treatment of pulmonary embolism.

Inari Medical Announces Publication of Results From the FLARE IDE Study

May 7, 2019—Inari Medical, Inc. announced that results from the 106-patient, prospective, multicenter FLARE investigational device exemption study of the company's FlowTriever mechanical pulmonary embolectomy device were published by Thomas Tu, MD, et al in Journal of the American College of Cardiology: Cardiovascular Interventions (2019;12:859–869).

NIH Grant Funds RESCUE Trial of Thrombolex Bashir Catheter

July 2, 2020—Thrombolex Inc. has announced that it was awarded a $3 million Small Business Innovation Research (SBIR) Direct-to-Phase II grant from the National Heart, Lung and Blood Institute (NHLBI) section of the National Institutes of Health to fund the company’s pivotal RESCUE trial under an investigational device exemption.

Enrollment Begins for Pivotal Trial of BiO2 Medical's Angel Catheter and IVC Filter

February 19, 2015—BiO2 announced that the first three patients have been enrolled for the Angel catheter clinical trial, a prospective, single-arm clinical investigation of the device.

Long-Term Results Presented From OPTALYSE PE Trial of Ekos Therapy For Pulmonary Embolism

February 6, 2018—BTG plc announced that 1-year results from the OPTALYSE PE trial were presented at ISET, the annual International Symposium on Endovascular Therapy held February 3–7 in Hollywood, Florida.

FLARE Will Study Inari's FlowTriever System to Treat Pulmonary Embolism

March 8, 2016—Inari Medical, Inc. announced that the US Food and Drug Administration has approved an investigational device exemption for a study to evaluate the safety and effectiveness of its FlowTriever retrieval/aspiration system.

Inari Medical's FlowTriever Studied for Treatment of Pulmonary Embolism

May 1, 2018—Inari Medical, Inc. recently announced that results from the FLARE clinical study were presented by Thomas Tu, MD, at the 2018 scientific sessions of the Society for Cardiovascular Angiography and Interventions, held April 25–28 in San Diego, California.

OPTALYSE PE Study Evaluates Shorter, Lower-Dose Thrombolysis With Ekos Therapy

May 22, 2017—BTG International announced that the results of the OPTALYSE PE trial showed that pulmonary embolism (PE) can be treated effectively with the company's Ekos EkoSonic endovascular system—an acoustic pulse thrombolysis therapy—during a much shorter period and at safer thrombolytic doses far below the current standard.

ULTIMA Study Supports EkoSonic System for PE Treatment

January 20, 2014—Ekos Corporation (Bothell, WA), a BTG International group company, announced that the results of the company’s ULTIMA (Ultrasound-Accelerated Thrombolysis of Pulmonary Embolism [PE]) trial were published by Nils Kilcher, MD, et al in Circulation. Dr.

Inari Medical Appoints Dr. Victor F. Tapson as VP of Medical Affairs

September 21, 2021—Inari Medical, Inc. a medical device company focused on the treatment of venous diseases, announced that the company has appointed Victor F. Tapson, MD, as Vice President of Medical Affairs.

Results Published From OPTALYSE PE Trial of BTG's Ekos System

July 23, 2018—BTG International announced the publication of the OPTALYSE PE trial results by Victor F. Tapson, MD, et al in Journal of the American College of Cardiology: Cardiovascular Interventions (2018:11;1401–1410). The findings were presented at the Society for Cardiovascular Angiography and Interventions scientific sessions, held April 25–28 in San Diego, California.